Pegylated IFN-?2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples